Cervical Cancer

Tool Compounds

Modeling Agent: 7,12-Dimethylbenz[a]anthracene; N-Nitroso-N-methylurea

Hypoxic Marker: Pimonidazole

Drugs Approved

Bleomycin sulfate

Tisotumab vedotin

NCCN Guidelines Recommendations ^[1]

First-Line Systemic Therapy: Pembrolizumab; Cisplatin; Paclitaxel; Bevacizumab; Topotecan

Subsequent-Line Systemic Therapy: Pembrolizumab; Tisotumab vedotin; Cemiplimab; Paclitaxel; Nab-Paclitaxel; Docetaxel; 5-FU; Gemcitabine; Pemetrexed; Topotecan; Vinorelbine ditartrate; Irinotecan

Chemotherapy Regimens

CARBOPLATIN-TAXOL: Carboplatin; Paclitaxel

GEMCITABINE-CISPLATIN: Gemcitabine HCl; Cisplatin

Antiviral Infection

Anti-HPV Infection: Isoprinosine; N-p-Tosyl-L-phenylalanine chloromethyl ketone; Vorinostat; A2ti-1; A2ti-2

Anti-HIV Infection: Doxorubicin HCl; Plerixafor; Triciribine; Birinapant; Cenicriviroc

ICIs

PD-1: Pembrolizumab; Dostarlimab; Cemiplimab; Camrelizumab; Sintilimab; Nivolumab; Serplulimab; Balstilimab

PD-L1: Atezolizumab; Durvalumab; Avelumab; Adebrelimab; Sugemalimab

CTLA-4: Nurulimab; Zalifrelimab; Quavonlimab; Ipilimumab; Tremelimumab

TIGHT: Tiragolumab; Vibostolimab; Domvanalimab; Ociperlimab

Anti-Angiogenesis ^[2]

VEGF: Bevacizumab; Pazopanib; Lapatinib; Brivanib

TKIs: Sunitinib; Imatinib

Angiotensin: Angiotensin II human Acetate; Angiotensin; Azilsartan; Olmesartan

Targeted Therapy (A) ^[3]

CD44: Bivatuzumab; Angstrom6

ALDH: Disulfiram; Daidzin; NCT-501; Alda 1; CM10

ABCG2: Ko143; RG14620; YHO-13177; KS176; 5,7-Dimethoxyflavone

NANOG: Amcasertib

BMI1: PTC-209; PTC-209 HBr; PRT4165; Unesbulin; PTC-028

Targeted Therapy (B) ^[3]

LGR5: Petosemtamab

OCT3/4: O4I2; O4I1

α-SMA: CCG-222740; Apamin

Vimentin: Withaferin A

KLF4: APTO-253

β-catenin: IWP-2; Laduviglusib; Capmatinib

c-Myc: 10058-F4; dBET6; 10074-G5

CSCs Marker ^[3]

NANOG: Amcasertib

KLF4: APTO-253

CD133: Amcasertib

Cd44: Bivatuzumab; Angstrom6

ALDH1: Disulfiram; NCT-501; CM10

ABCG2: Ko143; RG14620; YHO-13177; KS176; 5,7-Dimethoxyflavone

BMI1: PTC-209; PTC-209 HBr; PRT4165; Unesbulin; PTC-028

LGR5: Petosemtamab

EMT ^[3]

BMI1: PTC-209; PTC-209 HBr; PRT4165; Unesbulin; PTC-028

Vimentin: Withaferin A

Compound Library

FDA-approved Anticancer Drug Library

Anti-cancer Compound Library

Anti-cancer Compound Library-Ⅱ

Anti-cancer Metabolism Compound Library

Cambridge Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Angiogenesis Related compound Library

PI3K/Akt Inhibitor Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library